• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass.

作者信息

Nielsen L S, Andreasen P A, Grøndahl-Hansen J, Skriver L, Danø K

出版信息

FEBS Lett. 1986 Feb 17;196(2):269-73. doi: 10.1016/0014-5793(86)80261-7.

DOI:10.1016/0014-5793(86)80261-7
PMID:3081367
Abstract

Purified approximately 54 kDa plasminogen activator inhibitor from human fibrosarcoma cells was converted to an inactive form with slightly higher electrophoretic mobility by incubation with catalytic amounts of urokinase-type or tissue-type plasminogen activator. Serine proteinase inhibitors and a monoclonal antibody against urokinase-type plasminogen activator inhibited the conversion, indicating that it was caused by plasminogen activator-catalyzed proteolysis. These findings represent the first demonstration of a well-defined protein apart from plasminogen, constituting a substrate for plasminogen activators.

摘要

相似文献

1
Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass.
FEBS Lett. 1986 Feb 17;196(2):269-73. doi: 10.1016/0014-5793(86)80261-7.
2
Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.来自纤维肉瘤细胞的针对人54000分子量纤溶酶原激活物抑制剂的单克隆抗体——抑制剂中和及一步亲和纯化
Thromb Haemost. 1986 Apr 30;55(2):206-12.
3
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.来自人纤维肉瘤细胞的纤溶酶原激活物抑制剂能结合尿激酶型纤溶酶原激活物,而非其酶原。
J Biol Chem. 1986 Jun 15;261(17):7644-51.
4
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.利用单克隆抗体对人肿瘤细胞系中细胞外纤溶酶原激活剂及分子量约为54,000的纤溶酶原激活剂抑制剂的激素调节作用进行研究。
Mol Cell Endocrinol. 1986 May;45(2-3):137-47. doi: 10.1016/0303-7207(86)90141-3.
5
Plasminogen activator and its inhibitor in the experimental corneal wound.
Exp Eye Res. 1989 Mar;48(3):445-9. doi: 10.1016/s0014-4835(89)80012-0.
6
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.肿瘤坏死因子-α调节人肿瘤细胞系中尿激酶型纤溶酶原激活物和1型纤溶酶原激活物抑制剂的mRNA。
Mol Cell Endocrinol. 1989 Jan;61(1):87-96. doi: 10.1016/0303-7207(89)90192-5.
7
Production of proteases type plasminogen activator and their inhibitor in cornea.角膜中纤溶酶原激活物型蛋白酶及其抑制剂的产生。
Biochem Biophys Res Commun. 1989 May 15;160(3):1021-5. doi: 10.1016/s0006-291x(89)80104-4.
8
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.与纤维蛋白结合的1型纤溶酶原激活物抑制剂(PAI-1)与组织型纤溶酶原激活物(t-PA)或尿激酶型纤溶酶原激活物(u-PA)之间的相互作用。t-PA的指状结构域和kringle-2结构域介导t-PA/PAI-1复合物与纤维蛋白的结合。
J Clin Invest. 1989 Aug;84(2):647-55. doi: 10.1172/JCI114211.
9
Hormonal regulation of the release of plasminogen activators and of a specific activator inhibitor from endometrial tissue in culture.培养的子宫内膜组织中纤溶酶原激活剂及一种特异性激活剂抑制剂释放的激素调节。
Proc Soc Exp Biol Med. 1986 Sep;182(4):419-24. doi: 10.3181/00379727-182-42360.
10
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.人肉瘤细胞上尿激酶原和纤溶酶原的激活:一个具有表面结合反应物的蛋白水解系统。
J Cell Biol. 1989 May;108(5):1987-95. doi: 10.1083/jcb.108.5.1987.

引用本文的文献

1
MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.MUC1蛋白通过与NF-κB p65转录因子形成复合物并结合uPA启动子来诱导尿激酶型纤溶酶原激活剂(uPA),从而导致癌细胞侵袭性增强。
J Biol Chem. 2014 Dec 19;289(51):35193-204. doi: 10.1074/jbc.M114.586461. Epub 2014 Nov 4.
2
Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.纤溶酶原激活物抑制剂2作为原发性肺癌预后标志物的意义:纤溶酶原激活物抑制剂2降低与淋巴结转移的关联
Br J Cancer. 1998 Sep;78(6):833-9. doi: 10.1038/bjc.1998.588.
3
Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta.转化生长因子-β对A549人肺癌细胞中尿激酶型纤溶酶原激活物合成及活性的调节
J Cell Biol. 1988 Feb;106(2):451-9. doi: 10.1083/jcb.106.2.451.
4
Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.纤溶酶原激活物抑制剂-1(PAI-1)与人内皮细胞生长基质及细胞膜的关联。
J Cell Biol. 1987 Dec;105(6 Pt 1):2543-9. doi: 10.1083/jcb.105.6.2543.
5
Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.纤溶酶原激活物抑制剂与培养的牛平滑肌细胞的细胞外基质相关。
J Clin Invest. 1987 Oct;80(4):1082-9. doi: 10.1172/JCI113164.
6
The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells.碱性成纤维细胞生长因子和转化生长因子β对毛细血管内皮细胞中纤溶酶原激活物活性调节的相反作用。
J Cell Biol. 1987 Aug;105(2):957-63. doi: 10.1083/jcb.105.2.957.
7
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors.尿激酶型纤溶酶原激活剂:酶原、受体及抑制剂
J Cell Biol. 1987 Apr;104(4):801-4. doi: 10.1083/jcb.104.4.801.
8
Urokinase-dependent adhesion loss and shape change after cyclic adenosine monophosphate elevation in cultured rat mesangial cells.培养的大鼠系膜细胞中环磷酸腺苷升高后,尿激酶依赖性黏附丧失和形态改变。
J Clin Invest. 1988 Dec;82(6):1992-2000. doi: 10.1172/JCI113819.
9
Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.人单核细胞/巨噬细胞产生的纤溶酶原激活物特异性抑制剂。
J Exp Med. 1987 Feb 1;165(2):320-39. doi: 10.1084/jem.165.2.320.
10
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.Lewis肺癌中的1型纤溶酶原激活物抑制剂
Histochemistry. 1990;93(6):559-66. doi: 10.1007/BF00272198.